PEXA B Stock Overview
Develops and commercializes diagnostic products in various respiratory diseases, such as asthma, tuberculosis, cystic fibrosis, lung cancer, chronic airway inflammation, and chronic obstructive pulmonary diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
PExA AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.43 |
| 52 Week High | SEK 0.63 |
| 52 Week Low | SEK 0.30 |
| Beta | 0.82 |
| 11 Month Change | 9.14% |
| 3 Month Change | 8.31% |
| 1 Year Change | -8.12% |
| 33 Year Change | -74.56% |
| 5 Year Change | -85.57% |
| Change since IPO | -87.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| PEXA B | SE Life Sciences | SE Market | |
|---|---|---|---|
| 7D | -2.1% | 1.0% | 1.3% |
| 1Y | -8.1% | 62.2% | 21.8% |
Return vs Industry: PEXA B underperformed the Swedish Life Sciences industry which returned 62.2% over the past year.
Return vs Market: PEXA B underperformed the Swedish Market which returned 21.8% over the past year.
Price Volatility
| PEXA B volatility | |
|---|---|
| PEXA B Average Weekly Movement | 15.4% |
| Life Sciences Industry Average Movement | 8.3% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in SE Market | 12.2% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: PEXA B has not had significant price volatility in the past 3 months.
Volatility Over Time: PEXA B's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 3 | Tomas Gustafsson | pexa.se |
PExA AB (publ) develops and commercializes diagnostic products in various respiratory diseases, such as asthma, tuberculosis, cystic fibrosis, lung cancer, chronic airway inflammation, and chronic obstructive pulmonary diseases. Its research instrument helps lung researchers in the collection of microscopic particles and biomarkers for diseases in the small airways. The company offers PExA 2.0, an instrument for the non-invasive collection of particles in exhaled air.
PExA AB (publ) Fundamentals Summary
| PEXA B fundamental statistics | |
|---|---|
| Market cap | SEK 18.18m |
| Earnings (TTM) | -SEK 8.78m |
| Revenue (TTM) | SEK 1.32m |
13.7x
P/S Ratio-2.1x
P/E RatioIs PEXA B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PEXA B income statement (TTM) | |
|---|---|
| Revenue | SEK 1.32m |
| Cost of Revenue | SEK 1.19m |
| Gross Profit | SEK 138.20k |
| Other Expenses | SEK 8.92m |
| Earnings | -SEK 8.78m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.21 |
| Gross Margin | 10.44% |
| Net Profit Margin | -663.44% |
| Debt/Equity Ratio | 0% |
How did PEXA B perform over the long term?
See historical performance and comparison